대한본초학회지 (The Korea Journal of Herbology)

  • 제24권4호
  • /
  • Pages.215-224
  • /
  • 2009
  • /
  • 1229-1765(pISSN)
  • /
  • 2288-7199(eISSN)
대한본초학회 (The Korea Association of Herbology)
권호 표지
DOI QR코드

DOI QR Code

TNCB로 유발한 아토피피부염 생쥐 모델에서 천일염가미방(天日鹽加味方)과 청기해독산(淸肌解毒散)의 병용 효과

Suppressive Effects of Chenilyeomgamibang (CGB) and Chenggihaedok-san (CHS) on TNCB(trinitrochlorobenzene)-induced Atopic Dermtitis NC/Nga Mice Model

  • 이경미 (대전대학교 한의과대학 병리학교실) ;
  • 김선빈 (대전대학교 한의과대학 병리학교실) ;
  • 최학주 (대전대학교 한의과대학 병리학교실) ;
  • 최정준 (대전대학교 한의과대학 병리학교실) ;
  • 노성수 (대구한의대학교 한의과대학 본초학교실) ;
  • 김동희 (대전대학교 한의과대학 병리학교실)
  • Lee, Kyoung-Mee (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Gim, Seon-Bin (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Choi, Hak-Ju (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Choi, Jeong-June (Department of Pathology, College of Oriental Medicine, Daejeon University) ;
  • Roh, Seong-Soo (Department of Herbology, College of Oriental Medicine, Daegu Haany University) ;
  • Kim, Dong-Hee (Department of Pathology, College of Oriental Medicine, Daejeon University)
  • 발행 : 2009.12.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Objectives : Atopic dermatitis is a chronic inflammatory disease characterized by typically distributed eczematous skin lesion with pruritus, lichenification and dry skin. In this study, we performed to assess the therapeutic effects of co-treatment of Chenilyeomgamibang (CGB) and Chenggihaedok-san (CHS, C&C) on the TNCB(trinitrochlorobenzene)-induced atopic dermatitis in NC/Nga mice, characterized by the onset of atopic dermatitis along with an increase the number of inflammatory cells and dysregulation of Th2 cytokines. Methods : Defined amount of CGB was sprayed on mice skin and CHS was simultaneously orally administrated to TNCB treated NC/Nga mice for 5 weeks. The immune cell types were caracterized by flow cytometry using each specific antibody. The amount of Th2 cytokines in serum and splenocytes culture supernatant were measured by ELISA. Results : Administration of C&C significantly reduced clinical dermatitis severity including pruritus, edema, eczematous and erythema. Histological findings indicated that the thickening of epidermis/dermis and dermal infiltration of inflammatory cells were dramatically reduced. Flow cytometry analysis showed that infiltrated immune cell numbers of CCR3+, B220+/IgE+, Gr-1+/CD11b+, and CD117+ were significantly reduced in C&C-treated dorsal skin lesion. Furthermore, T cell composition rate in PBMC was also dramatically decreased by the treatment. C&C greatly down-regulated production of Th2 cytokines including IL-4, IL-5, IL-13 in the serum. The down- regulatory effects of C&C on these Th2 cytokines production were also detected in CD3/ CD28 activated splenocytes. Conclusions : These results indicated that C&C is a plausible therapeutic agent for treatment of atopic dermatitis through regulating the Th2 skewed immune system.

키워드

참고문헌

  1. Daniels J, Harper J. The epidemiology of atopic dermatitis. Hosp Med. 2002 ; 63 : 649-52. https://doi.org/10.12968/hosp.2002.63.11.1908
  2. Oh J, Kim K, Pyun B, Lee H, Choung J. Nationwide study for epiemiological change of atopic dermatitis in school aged children in 2003 in Korea. Pediatr Allergy Respir Dis (Korea). 2003 ; 13 : 227-37.
  3. Schultz Larsen F, Hanifin JM. Secular change in the occurrence of atopic dermatitis. Acta Derm Venereol Suppl (Stockh). 1992 ; 176 : 7-12.
  4. Hassan AS, Kaelin U, Braathen LR, Yawalkar N. Clinical and immunopathologic findings during treatment of recalcitrant atopic eczema with efalizumab. J Am Acad Dermatol. 2007 ; 56 : 217-21. https://doi.org/10.1016/j.jaad.2006.08.025
  5. Wollenberg A, Kraft S, Oppel T, Bieber T. Atopic dermatitis: pathogenetic mechanisms. Clin Exp Dermatol. 2000 ; 25 : 530-4. https://doi.org/10.1046/j.1365-2230.2000.00699.x
  6. Holden CA, Parish WE. Atopic dermatitis. Oxford : Blcackwell Science. 1998 : 681-708.
  7. Meagher LJ, Wines NY, Cooper AJ. Atopic dermatitis: review of immunopathogenesis and advances in immunosuppressive therapy. Australas J Dermatol. 2002 ; 43 : 247-54. https://doi.org/10.1046/j.1440-0960.2002.00610.x
  8. Cooper KD. Atopic dermatitis: recent trends in pathogenesis and therapy. J Invest Dermatol. 1994 ; 102 : 128-37. https://doi.org/10.1111/1523-1747.ep12371746
  9. Williams HC. Clinical practice. Atopic dermatitis. N Engl J Med. 2005 ; 352 : 2314-24. https://doi.org/10.1056/NEJMcp042803
  10. Leung DY, Bieber T. Atopic dermatitis. Lancet. 2003 ; 361 : 151-60. https://doi.org/10.1016/S0140-6736(03)12193-9
  11. Kimata H. Selective enhancement of production of IgE, IgG4, and Th2-cell cytokine during the rebound phenomenon in atopic dermatitis and prevention by suplatast tosilate. Ann Allergy Asthma Immunol. 1999 ; 82 : 293-5. https://doi.org/10.1016/S1081-1206(10)62611-7
  12. Hanifin JM, Cooper KD, Ho VC, Kang S, Krafchik BR, Margolis DJ, Schachner LA, Sidbury R, Whitmore SE, Sieck CK, Van Voorhees AS. Guidelines of care for atopic dermatitis, developed in accordance with the American Academy of Dermatology (AAD)/American Academy of Dermatology Association "Administrative Regulations for Evidence- Based Clinical Practice Guidelines". J Am Acad Dermatol. 2004 ; 50 : 391-404. https://doi.org/10.1016/j.jaad.2003.08.003
  13. 이동현. 防風通聖散 및 防風通聖散 加味方이 抗 알레르기와 免疫反應에 미치는 影響. 경희대학교대학원. 1990.
  14. 성현제. 防風通聖散의 鎭痛 消炎 解熱 및 抗菌作用 에 관한 實驗的 硏究. 경희대학교대학원. 1984.
  15. 김대근 외. 박하의 항알레르기 활성. 생약학회지. 1998 ; 29(3) : 248-53.
  16. 申淑正. 황금 추출물이 면역반응과 항균작용에 미치는 영향. 전주대학교 대학원. 1993
  17. Schultz Larsen F, Diepgen T, Svensson A. The occurrence of atopic dermatitis in north Europe: an international questionnaire study. J Am Acad Dermatol. 1996 ; 34 : 760-64. https://doi.org/10.1016/S0190-9622(96)90009-2
  18. Kiebert G, Sorensen SV, Revicki D, Fagan SC, Doyle JJ, Cohen J, Fivenson D. Atopic dermatitis is associated with a decrement in health-related quality of life. Int J Dermatol. 2002 ; 41 : 151-8. https://doi.org/10.1046/j.1365-4362.2002.01436.x
  19. Lapidus CS, Kerr PE. Social impact of atopic dermatitis. Med Health R I. 2001 ; 84 : 294-5.
  20. Hon KL, Leung TF, Ng PC, Lam MC, Kam WY, Wong KY, Lee KC, Sung YT, Cheng KF, Fok TF, Fung KP, Leung PC. Efficacy and tolerability of a Chinese herbal medicine concoction for treatment of atopic dermatitis: a randomized, doubleblind, placebo-controlled study. Br J Dermatol. 2007 ; 157 : 357-63. https://doi.org/10.1111/j.1365-2133.2007.07941.x
  21. 이주은 외. 방풍갈근탕의 항알레르기효과에 관한 연구. 동의생리병리학회지. 2007 ; 21 : 1118-26.
  22. 장선일 외. 천연물 유래 Th2 케모카인 억제제 발굴에 의한 새로운 아토피 피부염 치료기술 개발: 아토피 피부염 모델 NC/Nga 마우스에서 고삼 추출액의 억제 효과. 대한한의방제학회지. 2009 ; 17 : 141-51.
  23. 곽노규 외. 연교패독산 물 추출물의 마우스 Th1/Th2 사이토카인 조절에 의한 항알레르기 효과. 동의생리병리학회지. 2006 ; 20 : 844-52.
  24. Leung DY. Pathogenesis of atopic dermatitis. J Allergy Clin Immunol. 1999 ; 104 : S99-108. https://doi.org/10.1016/S0091-6749(99)70051-5
  25. Morren MA, Przybilla B, Bamelis M, Heykants B, Reynaers A, Degreef H. Atopic dermatitis: triggering factors. J Am Acad Dermatol. 1994 ; 31 : 467-73. https://doi.org/10.1016/S0190-9622(94)70213-6
  26. Valenta R, Seiberler S, Natter S, Mahler V, Mossabeb R, Ring J, Stingl G. Autoallergy: a pathogenetic factor in atopic dermatitis? J Allergy Clin Immunol. 2000 ; 105 : 432-7. https://doi.org/10.1067/mai.2000.104783
  27. Muller KM, Jaunin F, Masouye I, Saurat JH, Hauser C. Th2 cells mediate IL-4-dependent local tissue inflammation. J Immunol. 1993 ; 150 : 5576-84.
  28. 李博鑑. 皮科證治槪要. 人民衛生出版社. 1999 : 47-8.
  29. 徐宜厚 외. 皮膚病中醫診療學. 人民衛生出版社. 1995 : 254, 310, 316.
  30. 이원문 외. 皮膚性病手冊. 人民衛生出版社. 2004 : 193.
  31. 공남미 외. 아토피피부염의 양․한방적 고찰. 대한외관과학회지 1999 ; 12 : 241-53.
  32. 廖新华 외. 皮肤病驗方600首. 上海中医葯大学出版社. 2001 : 128-30.
  33. 한방병리학 교재편찬위원회. 한방병리학. 한의문화사. 2008 : 37-42, 52-8.
  34. 김선빈. 아토피 피부염에 대한 황토가미방과 청삼가 미방의 내외치 겸용에 관한 연구. 대전대학교 대학원. 2009.
  35. 손대범 외. 淸肌散과 三黃洗劑加味方 병용이 NC/Nga mice의 아토피 피부염에 미치는 영향. 동의생리병리학회지. 2008 ; 22(5) : 1168-77.
  36. Leung DY. Atopic dermatitis: the skin as a window into the pathogenesis of chronic allergic diseases. J Allergy Clin Immunol. 1995 ; 96 : 302-18 ; quiz 319. https://doi.org/10.1016/S0091-6749(95)70049-8
  37. Garcia-Montero AC, Jara-Acevedo M, Teodosio C, Sanchez ML, Nunez R, Prados A, Aldanondo I, Sanchez L, Dominguez M, Botana LM, Sanchez- Jimenez F, Sotlar K, Almeida J, Escribano L, Orfao A. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood. 2006 ; 108 : 2366-72. https://doi.org/10.1182/blood-2006-04-015545
  38. Yawalkar N, Uguccioni M, Scharer J, Braunwalder J, Karlen S, Dewald B, Braathen LR, Baggiolini M. Enhanced expression of eotaxin and CCR3 in atopic dermatitis. J Invest Dermatol. 1999 ; 113 : 43-8. https://doi.org/10.1046/j.1523-1747.1999.00619.x
  39. Bieber T, Rieger A, Stingl G, Sander E, Wanek P, Strobel I. CD69, an early activation antigen on lymphocytes, is constitutively expressed by human epidermal Langerhans cells. J Invest Dermatol. 1992 ; 98 : 771-6. https://doi.org/10.1111/1523-1747.ep12499948
  40. Dubois GR, Bruijnzeel-Koomen CA, Bruijnzeel PL. IL-4 induces chemotaxis of blood eosinophils from atopic dermatitis patients, but not from normal individuals. J Invest Dermatol. 1994 ; 102 : 843-6. https://doi.org/10.1111/1523-1747.ep12382362